APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer
ACS Omega · 22.07.2025 · 10 (28) · 31099-31107
DOI: 10.1021/acsomega.5c04710 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Omega, online erschienen am 14.07.2025. Verfasst von Lei Liang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, Guangdong, China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, Sanming Project of Medicine in Shenzen Municipality, Shenzhen Science and Technology Innovation Program.
Abstract (Originalsprache)
The murine double minute 2 (MDM2)-p53 interaction inhibitor APG-115 demonstrates therapeutic potential in advanced malignancies. However, its molecular mechanism, especially for programmed death ligand 1 (PD-L1) immunotherapy modulation, remains poorly understood in thyroid cancer (TC). Herein, we conducted a series of in vitro and in vivo studies to investigate the therapeutic effect of APG-115 and the underlying molecular mechanisms in TC. We performed Cell Counting Kit (CCK-8) and cell scratch assay to assess the effect of APG-115 on the biological behavior of TC cells. Meanwhile, we performed animal experiments to investigate the therapeutic effect of APG-115 on TC in vivo. TC patient-derived organoids were further used to evaluate the potential value for clinical application of APG-115. Our results showed that APG-115 exhibited beneficial therapeutic effects in TC both in vitro and in vivo. Mechanistically, APG-115 restored the p53 antitumor effects by blocking MDM2-p53 binding and upregulating the PD-L1 expression. APG-115 downregulated Solute Carrier Family 7 Member 11 (SLC7A11) expression, contributing to lipid peroxidation and affecting PD-L1 expression in TC. Our study expands the clinical application value of APG-115 in cancer treatment, especially by further exploring the complex interplay between APG-115, PD-L1 immunotherapy, and ferroptosis.
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, Guangdong, China.
- Shantou University Medical College, Shantou 515041, Guangdong, China.
- Department of Central Laboratory, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, Guangdong, China.
- Department of Thyroid and Breast Surgery, Peking University Shenzhen Hospital, 1120 Lianhua Road, Shenzhen 518036, Guangdong, China.
ORCID-Profile: Yongsheng Zhao, Haibo Chen
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- Sanming Project of Medicine in Shenzen Municipality
- Shenzhen Science and Technology Innovation Program
- General Program for Clinical Research at Peking University Shenzhen Hospital
Zitieren
APA
Liang, L., Chen, Z., Lei, D., Mo, C., Lan, D., Ke, J., Wang, W., Yang, Z., Guo, X., Chen, D., Zhao, Y., & Chen, H. (2025). APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer. ACS Omega, 10(28), 31099-31107. https://doi.org/10.1021/acsomega.5c04710
Vancouver
Liang L, Chen Z, Lei D, Mo C, Lan D, Ke J, et al. APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer. ACS Omega. 2025;10(28):31099-31107. doi:10.1021/acsomega.5c04710
BibTeX
@article{Liang2025,
author = {Liang, Lei and Chen, Zhulan and Lei, Defeng and Mo, Chunwei and Lan, Deren and Ke, Juanru and Wang, Weiqi and Yang, Zhuo and Guo, Xin and Chen, Dong and Zhao, Yongsheng and Chen, Haibo},
title = {APG-115 Induces SLC7A11-Mediated Ferroptosis and Upregulates PD-L1 Expression in Thyroid Cancer},
journal = {ACS Omega},
year = {2025},
volume = {10},
number = {28},
pages = {31099--31107},
doi = {10.1021/acsomega.5c04710}
}
EUVIMED